Search for stock quotes, financial statistics and more
Leede Financial has initiated coverage of Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Q... Read More
Research Capital analyst Andre Uddin reiterated a “Speculative Buy” rating and C$12.00 target pr... Read More
Research Capital analyst Andre Uddin maintained a “Speculative Buy” rating and C$12.00 target pr... Read More
Research Capital’s Andre Uddin said August 13 he remains focused on Eupraxia Pharmaceuticals’ (E... Read More
Following results that have sent the stock northward, Research Capital analyst Andre Uddin remains b... Read More
Share
Tweet
pin
Share